Eli Lilly and Company (LLY) — closed signal from February 4, 2026
Partial Published before the outcome was known, scored automatically when the window closed on May 5, 2026.
Predicted vs. what happened
What happened
Reached 27% of the predicted growth at its peak, without hitting the target.
The thesis — published February 4, 2026
Lilly reported much better-than-expected sales and raised its outlook for its diabetes and weight-loss medicines. That pushed big investors to buy, lifting the stock. Near term this momentum can continue if the price steadies after the earnings move, but expect big day-to-day swings. Prefer buying dips and trimming quick rallies; watch for competition or pricing headlines.
Primary drivers
- Big sales beat and stronger long-term outlook for key drugs
- More interest from big institutional investors after earnings
- Large healthcare name benefits when investors rotate into the sector
- Main near-term risk is new competition or negative pricing news
How it played out
LLY: target was not reached
On 2026-02-04, Lyra published a short-term LLY thesis at 1077.97. It expected 12% growth toward 1207.33. The thesis pointed to much better-than-expected sales, a stronger long-term outlook for key drugs, more institutional interest after earnings, healthcare rotation, and the risk of competition or negative pricing headlines.
Inside the window from 2026-02-04 to 2026-05-05, LLY peaked at 1114 on 2026-02-04, a 3.3% gain. It stayed below 1207.33 and never reached the target. The stock ended at 988.87. The thesis partly played out early, but the full target missed.
What happened during the window
On 2026-04-01, The Guardian reported that U.S. regulators approved Lilly's oral weight-loss drug orforglipron, sold as Foundayo. The same report said the daily pill would begin shipping through LillyDirect on the following Monday.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.